Curran Monique, Simpson Dene, Perry Caroline
Adis International Limited, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, Auckland 1311, New Zealand.
Drugs. 2003;63(17):1855-78. doi: 10.2165/00003495-200363170-00006.
Ertapenem, a carbapenem antibacterial, has in vitro activity against many Gram- negative (including Enterobacteriaceae) and Gram-positive aerobic and anaerobic bacteria that are commonly associated with various infections.Once-daily parenteral (intravenous or intramuscular) ertapenem 1g was as effective as comparator antimicrobial agents (piperacillin/tazobactam or ceftriaxone +/- metronidazole) in patients with bacterial infections in randomised, double-blind, multicentre clinical trials. Response rates with ertapenem were 84% and 87% (combined microbiological and clinical) in patients with complicated intra-abdominal infections (CIAI), 82% (clinical) in patients with complicated skin and skin structure infections (CSSSI), 86% and 92% (microbiological) in patients with complicated urinary tract infections (CUTI), 92% (clinical) in patients with community-acquired pneumonia (CAP) associated with typical pathogens and 94% (clinical) in patients with acute pelvic infection. Respective response rates were statistically equivalent to those with comparators (81-94%). The efficacy of ertapenem was equivalent to that of piperacillin/tazobactam in patients infected with Enterobacteriaceae or anaerobes and to ceftriaxone in patients infected with Enterobacteriaceae. Ertapenem was generally well tolerated by patients with bacterial infections, with most adverse events being mild to moderate in severity. The most common ertapenem-associated adverse events were diarrhoea, infused vein complication, nausea, headache, vaginitis in females, phlebitis and/or thrombophlebitis and vomiting.
Ertapenem is a broad-spectrum parenteral antibiotic with activity against many Gram-negative (including Enterobacteriaceae) and Gram-positive aerobic and anaerobic bacteria and is suitable for once-daily administration. Ertapenem has a role in the treatment of CAP associated with typical respiratory pathogens and is of particular value in the treatment of polymicrobial infections (such as CIAI, CSSSI, CUTI and acute pelvic infections), especially where Enterobacteriaceae and anaerobic bacteria are involved.
厄他培南是一种碳青霉烯类抗菌药物，对许多革兰氏阴性菌（包括肠杆菌科细菌）以及革兰氏阳性需氧菌和厌氧菌具有体外活性，这些细菌通常与各种感染相关。在随机、双盲、多中心临床试验中，每日一次静脉或肌内注射1g厄他培南，对于细菌感染患者，其疗效与对照抗菌药物（哌拉西林/他唑巴坦或头孢曲松±甲硝唑）相当。在复杂性腹腔内感染（CIAI）患者中，厄他培南的（微生物学和临床综合）有效率为84%和87%；在复杂性皮肤和皮肤结构感染（CSSSI）患者中，临床有效率为82%；在复杂性尿路感染（CUTI）患者中，微生物学有效率为86%和92%；在由典型病原体引起的社区获得性肺炎（CAP）患者中，临床有效率为92%；在急性盆腔感染患者中，临床有效率为94%。各自的有效率与对照药物（81 - 94%）在统计学上相当。对于感染肠杆菌科细菌或厌氧菌的患者，厄他培南的疗效与哌拉西林/他唑巴坦相当；对于感染肠杆菌科细菌的患者，其疗效与头孢曲松相当。细菌感染患者对厄他培南总体耐受性良好，大多数不良事件的严重程度为轻至中度。与厄他培南相关的最常见不良事件为腹泻、输注静脉并发症、恶心、头痛、女性阴道炎、静脉炎和/或血栓性静脉炎以及呕吐。
厄他培南是一种广谱肠外抗生素，对许多革兰氏阴性菌（包括肠杆菌科细菌）以及革兰氏阳性需氧菌和厌氧菌具有活性，适合每日一次给药。厄他培南在治疗由典型呼吸道病原体引起的CAP中发挥作用，在治疗多微生物感染（如CIAI、CSSSI、CUTI和急性盆腔感染），尤其是涉及肠杆菌科细菌和厌氧菌的感染中具有特殊价值。
Zotero 插件